Monday May 29th 2017

Teva marketing strategies investigated by U.S. Attorney’s Office

Teva Pharmaceuticals Ltd. disclosed Monday it recently received a civil investigative demand from the U.S. Attorney’s Office in New York City seeking documents and information related to the company’s sales, marketing and promotion of two products: Copaxone and Azilect. Copaxone is used to treat multiple sclerosis. Azilect is medicine for patients suffering from Parkinson’s disease. The U.S. Attorney’s Office is seeking information on the sales practices for the two drugs from Jan. 1, 2006… (Source: bizjournals.com Health Care:Biotechnology headlines)

Continued here:

Teva marketing strategies investigated by U.S. Attorney’s Office

Leave a Comment

More from category

New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep
New sleep system helps profoundly disabled 5-year-old boy with complex care needs to get full night’s sleep

A 5-year-old boy, who is profoundly disabled and has complex needs, has been given his first full night’s sleep [Read More]

Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis
Revisions Underway to McDonald Criteria on MS Diagnosis Revisions Underway to McDonald Criteria on MS Diagnosis

An expert panel is tackling the first revision to the multiple sclerosis diagnostic criteria in 7 years. Among proposed [Read More]

Connecticut State Budget Call to Action
Connecticut State Budget Call to Action

/About-the-Society/News/Connecticut-State-Budget-Call-to-Action [Read More]

A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis
A Surge of New Drug Data in Multiple Sclerosis A Surge of New Drug Data in Multiple Sclerosis

Medscape sits down with two neurologists to discuss advances in multiple sclerosis as presented at this year's American [Read More]

Progress on Bills to Address Step Therapy
Progress on Bills to Address Step Therapy

/About-the-Society/News/Progress-on-Bills-to-Address-Step-Therapy [Read More]